Weakness in tools such as ILMN ($59.30) down 15% is hurting biotech. Also our mid cap biopharma index is down 2.5% . So the NASDAQ-100 is favored due to the inclusion of AAPL, AMZN, INTC and MSFT etc and larger cap biotech stocks.
Weakness in tools such as ILMN ($59.30) down 15% is hurting biotech. Also our mid cap biopharma index is down 2.5% . So the NASDAQ-100 is favored due to the inclusion of AAPL, AMZN, INTC and MSFT etc and larger cap biotech stocks.